22nd Century Group (NASDAQ:XXII) Stock Passes Below 50 Day Moving Average – What’s Next?

22nd Century Group, Inc (NASDAQ:XXII)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.03 and traded as low as $1.26. 22nd Century Group shares last traded at $1.37, with a volume of 60,619,066 shares.

22nd Century Group Stock Performance

The company’s 50-day simple moving average is $3.03 and its 200 day simple moving average is $10.30. The company has a current ratio of 2.42, a quick ratio of 1.83 and a debt-to-equity ratio of 0.03. The stock has a market cap of $986,400.00, a P/E ratio of 0.00 and a beta of 0.77.

Hedge Funds Weigh In On 22nd Century Group

An institutional investor recently raised its position in 22nd Century Group stock. Anson Funds Management LP grew its position in shares of 22nd Century Group, Inc (NASDAQ:XXII) by 677.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 763,212 shares of the biotechnology company’s stock after buying an additional 665,000 shares during the quarter. Anson Funds Management LP owned 149.65% of 22nd Century Group worth $588,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.